drugset / Trial / NCT00999583

High Dose of Erythropoietin Analogue After Cardiac Arrest

NCT00999583 ↗

RandomizedParallel-groupSingle-blindTreatment

Summary

The investigators hypothesised that the neuroprotective effects of erythropoietin and its analogues could lead to an improve outcome after cardiac arrest. To test this hypotheses, the investigators designed a randomized, multicentre, simple blind trial in which all participating patients will be receive usual treatments and 50% of them will also receive a high dose of epoetin alpha (an analogue of erythropoietin) in an "add on" fashion. The main end point will be the proportion of patients in each arm who will reach at day 60 the best level of recovery, using a 5 level score.

Timeline

Start
2009-10
Primary completion
2013-07
Completion
2014-05

Outcome

Missed primary endpoint

paper early administration of erythropoietin plus standard therapy did not confer a benefit PMID 27364049 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject EPOETINE ALPHA Unknown 40000 iu Intravenous